About this trial
This trial is for adults with multiple myeloma who have completed at least two years of maintenance treatment may take part in this study. Participants will be grouped based on whether their disease is still detectable or whether they have reached a deep remission, including those who have become MRD‑negative and may choose either to continue or to stop maintenance therapy. The final number of participants will depend on how many eligible patients are treated at Cork University Hospital.
Patient Profile
Patients with Multiple Myeloma
Where’s this trial being run?
Cork University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | Discontinuation Study |
|---|---|
| Number: | 20-28 |
| Full Title: | Discontinuation of Maintenance Therapy for the Patients Diagnosed With Multiple Myeloma in Sustainable Minimal Residual Disease (MRD) Negative Remission Without High Risk Features |
| Principal Investigator: | Dr Vitaliy Mykytiv |
|---|---|
| Type: | Collaborative |
| Sponsor: | University College Cork |
| Recruitment Started: |
Global: Ireland: Aug 2023 |
| Global Recruitment Target: | |
|---|---|
| Ireland Recruitment Target: | 70 |